Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | ITGAL | P20701 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CRHBP | P24387 | 2/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6432577 | 0.89 | LMNA (0.52) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL17449200 | 0.89 | LMNA (0.52) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL14004222 | 0.82 | LMNA (0.46) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL15522148 | 0.75 | — | — | |
| SCHEMBL14004235 | 0.72 | LMNA (0.38) | LMNACRHBPCRHR2SMN1; SMN2HTT | |
| SCHEMBL14004231 | 0.72 | LMNA (0.38) | LMNACRHBPCRHR2SMN1; SMN2HTT | |
| SCHEMBL6851405 | 0.69 | — | — | |
| SCHEMBL24799980 | 0.68 | CA1 (0.36) | — | |
| SCHEMBL24773474 | 0.66 | LMNA (0.50) | ITGB2ICAM1ITGALLMNACRHBP | |
| Hydrochloric Acid SCHEMBL4190811 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723384-B2 | Keto lactam compounds and use thereof | ABBOTT GMBH & CO. KG. (DE) | 2010-05-25 | — | — | US | disclosed |
| EP-1692129-B1 | KETO LACTAM COMPOUNDS AND USE THEREOF | ABBOTT GMBH & CO KG (DE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070219182-A1 | Keto Lactam Compounds and Use Thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219182-A1 | Keto Lactam Compounds and Use Thereof | OPRD1, DRD3, OPRK1 | ITGB2 2636/4885ICAM1 3749/4885ITGAL 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.